A subset of high‐grade sarcomas with myogenic differentiation are associated with recurrent FGFR fusions
The Journal of Pathology: Clinical Research · 2026-07 · 12 (4)
DOI: 10.1002/2056-4538.70094 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 25.05.2026. Verfasst von Maximus Cf Yeung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong. Hauptthemen laut MEDLINE: Sarcoma, Receptor, Fibroblast Growth Factor, Type 1, Biomarkers, Tumor, Soft Tissue Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Kristen Ann Carr Fund.
Abstract (Originalsprache)
Recurrent fusions involving FGFR1‐4 genes have been previously described in rare subsets of mostly benign chondroid and mesenchymal neoplasms involving bone and soft tissue. However, a more comprehensive analysis of sarcomas associated with FGFR fusions, including their incidence and histotypes, has not been performed. Triggered by an FGFR1 ‐rearranged unclassified high‐grade sarcoma with myogenic differentiation, we investigated our molecular database for sarcomas with FGFR gene fusions to assess their recurrent potential and morphologic spectrum. A total of six unclassified sarcomas were identified, occurring in five females and one male, with a median age of 66.5 years. Tumors were located in the uterus and retroperitoneal/trunk soft tissue. Histologically, all tumors were high grade, composed predominantly of spindle cell morphology with variable cytologic atypia, high mitotic activity, and areas of necrosis. By immunohistochemistry, all tumors demonstrated evidence of myogenic differentiation, with focal or diffuse positivity for one or more markers (desmin, h‐caldesmon, smooth muscle actin). However, none of the cases displayed diagnostic features of leiomyosarcoma or other known pathologic entities. Molecular studies revealed recurrent fusions involving FGFR1 ( n = 3), FGFR2 ( n = 1), and FGFR4 ( n = 2), retaining the kinase domain. Additional recurrent genomic alterations included TP53 mutations, CDKN2A homozygous deletions, and RB1 alterations. Most patients followed an aggressive clinical course, including metastases and disease‐related mortality. These findings expand the spectrum of sarcomas driven by FGFR gene fusions, underscoring the importance of molecular testing for accurate diagnosis and potential targeted therapy in high‐grade sarcomas with myogenic features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Carla Saoud, Cristina R Antonescu
Förderung
- NCI NIH HHS
- NIH HHS
- Kristen Ann Carr Fund
- Cycle for Survival
- National Institutes of Health
Zitieren
APA
Yeung, M. C., Saoud, C., Chiang, S., Hameed, M., & Antonescu, C. R. (2026). A subset of high‐grade sarcomas with myogenic differentiation are associated with recurrent FGFR fusions. The Journal of Pathology: Clinical Research, 12(4). https://doi.org/10.1002/2056-4538.70094
Vancouver
Yeung MC, Saoud C, Chiang S, Hameed M, Antonescu CR. A subset of high‐grade sarcomas with myogenic differentiation are associated with recurrent FGFR fusions. The Journal of Pathology: Clinical Research. 2026;12(4). doi:10.1002/2056-4538.70094
BibTeX
@article{Yeung2026,
author = {Yeung, Maximus Cf and Saoud, Carla and Chiang, Sarah and Hameed, Meera and Antonescu, Cristina R},
title = {A subset of high‐grade sarcomas with myogenic differentiation are associated with recurrent FGFR fusions},
journal = {The Journal of Pathology: Clinical Research},
year = {2026},
volume = {12},
number = {4},
doi = {10.1002/2056-4538.70094}
}
EUVIMED